Press Releases on January 5, 2024 - EIN Presswire - Press Release Distribution Service

Published on January 5, 2024 - 13:11 GMT

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)

Research Triangle Park, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that it is initiating GenePHIT (Gene …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on January 5, 2024 - 13:11 GMT

Rugged Handheld Devices Market size to grow by USD 2.48 billion between 2023-2028 | The strategic collaborations among market ...

New York, Jan. 05, 2024 (GLOBE NEWSWIRE) -- In a recent Technavio report titled Rugged Handheld Devices Market, it is projected that the market will grow at a rapid pace in the coming years. The market size is estimated to increase by USD 2.48 billion, …

Distribution channels: Book Publishing Industry, Media, Advertising & PR ...

Published on January 5, 2024 - 13:05 GMT

Axial Therapeutics to Present at Upcoming Conferences

WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart …

Distribution channels: Culture, Society & Lifestyle, Technology ...

Published on January 5, 2024 - 13:05 GMT

Largest Ever Real-World Evidence Study of Ambulatory Cardiac Monitoring Demonstrates Clinical Superiority of iRhythm's Zio Long-...

Findings published in the American Heart Journal show higher clinical diagnostic yield and lower odds of retesting with Zio long-term continuous monitoring service (LTCM) compared to other LTCM and ambulatory cardiac monitoring (ACM) products LTCM was …

Distribution channels: Media, Advertising & PR, Technology ...

Published on January 5, 2024 - 13:05 GMT

Spero Therapeutics Provides Corporate Update and 2024 Outlook

In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in PIVOT-PO Phase 3 trial for tebipenem HBr in cUTI patients. Entitled to receive $95 million in development …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on January 5, 2024 - 13:02 GMT

Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on January 5, 2024 - 13:01 GMT

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan ...

Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to initiate expansion in Q2 2024 and announce initial clinical data in mid-2024 Phase 1 clinical trial of XMT-2056, …

Distribution channels:

Published on January 5, 2024 - 13:01 GMT

MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation

Lykos Therapeutics, formerly known as MAPS PBC, announced the close of Series A financing to support regulatory and pre-launch activities for MDMA-assisted therapy for PTSD MAPS now shares ownership of Lykos Therapeutics with mission-aligned investors, …

Distribution channels: Business & Economy, Companies ...